ALMS.US Alumis Inc

Healthcare Biotechnology USA Stocks
5.60 USD
Close of Nov 14, 2026
5.44 31.35
Market cap
USD 725M
P/E
-
P/B
1.75x
ROE
-116.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALMS.US undervalued?

Graham number

The Graham number of Alumis Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alumis Inc fundamental analysis

No fundamental analysis for Alumis Inc yet.

Alumis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alumis Inc

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab…

Full company profile